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Abstract
Inactivation of the RB tumor suppressor and activation of the MYC family of oncogenes are frequent events in a large
spectrum of human cancers. Loss of RB function and MYC activation are thought to control both overlapping and distinct
cellular processes during cell cycle progression. However, how these two major cancer genes functionally interact during
tumorigenesis is still unclear. Here, we sought to test whether loss of RB function would affect cancer development in a
mouse model of c-MYC-induced hepatocellular carcinoma (HCC), a deadly cancer type in which RB is frequently inactivated
and c-MYC often activated. We found that RB inactivation has minimal effects on the cell cycle, cell death, and
differentiation features of liver tumors driven by increased levels of c-MYC. However, combined loss of RB and activation of
c-MYC led to an increase in polyploidy in mature hepatocytes before the development of tumors. There was a trend for
decreased survival in double mutant animals compared to mice developing c-MYC-induced tumors. Thus, loss of RB
function does not provide a proliferative advantage to c-MYC-expressing HCC cells but the RB and c-MYC pathways may
cooperate to control the polyploidy of mature hepatocytes.
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Introduction
Cancer is a complex disease that often progresses slowly due to
the gradual accumulation of genetic and epigenetic alterations
over time [1,2]. Typically, tumor cells harbor mutations that
activate oncogenes and inactivate tumor suppressors. The
combination of these alterations promotes deregulated cell
division, one of the hallmarks of the cancer phenotype [1].
Despite this universal property of tumors, many outstanding
questions remain, including whether the order of the successive
alterations is critical to cellular transformation and how mutations
in cancer pathways cooperate in the course of the disease.
The Retinoblastoma protein (RB) is a potent tumor suppressor
that restricts S phase entry by inhibiting the activity of the E2F
family of transcription factors [3]. Early in G1, activation of
Cyclin/CDK complexes by mitogenic signals results in RB
phosphorylation and functional inactivation, thus allowing E2F
family members to transcribe genes necessary for cell cycle
progression [4]. In addition to this well-described function of RB,
emerging evidence indicates that RB also normally promotes
differentiation in multiple lineages [5,6,7,8,9,10,11] and protects
cells from the accumulation of genomic alterations [12,13,
14,15,16,17]. Due to the critical influence of RB in the control
of cell cycle progression, it is not surprising that RB or members
of the RB pathway are mutated in nearly all human cancers
[18,19].
c-MYC (hereafter referred to as MYC) is a transcription factor
that heterodimerizes with its partner MAX in order to control the
expression of a large program of genes that promote proliferation,
cell death, cell growth, and cellular differentiation [20,21,22,23].
In resting cells, MYC activity is often minimal because of low
mRNA and protein levels; in contrast, MYC activity is strongly
induced in tumor cells by multiple mechanisms, including
increased transcription, stabilization of the protein, gene amplifi-
cation, and chromosomal translocation [24,25]. MYC activation is
a common feature of many human cancers, including cancers with
mutations in the RB pathway [20,21,22,26].
Hepatocellular carcinoma (HCC) is the third most common
cause of cancer death in the world with more than 500,000 deaths
a year [27]; the number of HCC cases increases every year [28].
While several causal agents for HCC have been identified,
including infection with hepatitis B and C viruses (HBV and
HCV), there is no effective treatment for this cancer type, in part
because the molecular and cellular mechanisms of HCC
development are still poorly understood [29,30,31]. MYC is
amplified in up to 50% of HCC cases, suggesting a key role for
MYC activation in the development of these tumors [32,33,34].
Similarly, inactivation of the RB pathway is found in more than
two-thirds of human HCCs by several mechanisms, including
inhibition of p16
INK4a and its family member p15
INK4b, increased
expression of Cyclin D1, and loss of RB function by phosphor-
ylation, protein degradation, or gene mutation [35,36].
Mouse models carrying mutations commonly found in human
tumors provide an opportunity to investigate the mechanisms of
tumorigenesis in vivo. A mouse model of human HCC with
inducible expression of MYC in adult liver cells has shown that
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however, these tumors develop with a prolonged latency,
suggesting that other genetic alterations are necessary to generate
HCC, including mutations in the p53 pathway [32,37,38,39,40].
The frequency of MYC activation and loss of RB pathway
function in human HCC suggests that these two pathways may
interact during tumorigenesis in the liver. However, whether or
not inactivation of RB can cooperate with MYC in the formation
of murine HCC has yet to be demonstrated. In this report, we use
a mouse model that allows us to conditionally delete the Rb gene
and overexpress MYC specifically in the liver. We show that loss of
RB has minimal effects on the development of HCC initiated by
the overexpression of MYC, suggesting that these two cancer
genes share many functions in liver cells undergoing tumorigenic
transformation.
Results
Combined activation of MYC and inactivation of RB in the
liver of adult mice results in the development of
hepatocellular carcinoma
To investigate the potential interactions between MYC
overexpression and RB loss of function in HCC, we bred
conditional mutant Rb
lox/lox mice [41] with LAP-tTA TRE-MYC
mice, in which expression of a human MYC cDNA can be induced
specifically in the liver [32,42] (Figure 1A). We found that, as
previously shown [32,42], expression of MYC in the liver of adult
mice (‘‘MYC mutant mice’’) resulted in the development of liver
tumors. We used intrasplenic injection of an adenoviral vector
expressing the Cre recombinase (Ad-Cre) to specifically delete Rb
in the adult liver and found that loss of Rb was not sufficient to
initiate liver cancer development, as previously shown [43,44]
(data not shown, see below). MYC/Rb double mutant mice
developed liver tumors composed of multiple fleshy vascular
nodules resembling MYC mutant tumors (data not shown). Total
RNA from tumors macro-dissected at the surface of the liver
showed high levels of expression of MYC compared to control liver
samples, independent of the presence or the absence of Rb,a s
expected (Figure 1B). Immunoblot analysis of liver extracts
revealed high levels of the MYC protein in all tumor samples
compared to controls (Figure 1C). PCR analysis of genomic DNA
isolated from tumors showed deletion of Rb in all the double
mutant tumors examined (n=6); no Rb deletion was observed in
mice expressing the MYC transgene and infected with an Ad-GFP
control adenovirus (n=6) (Figure 1D). Quantitative RT-PCR
(RT-qPCR) analysis of total RNA extracted from MYC/Rb double
mutant tumors showed a decrease in Rb levels compared to MYC
mutant tumors (Figure 1E). These data showed that deletion of Rb
in the liver of the infected mice was efficient and not counter-
selected during the development of HCC initiated by activation of
MYC.
When we analyzed livers from MYC and MYC/Rb mutant mice,
we found that tumors from both genotypes were composed of
hepatocellular neoplasms characterized by sheets of cells with
occasional mitotic figures, slightly pleomorphic nuclei, and
prominent nucleoli (Figure 2A). Examples from each genotype
showed a range of differentiation between well- and moderately-
differentiated HCC without an obvious tendency in the presence
of either genotype. In addition, tumors from both genotypes
expressed levels of Albumin, a marker of hepatocytes, that were
lower than those found in control livers. Levels of Cytokeratin 19
(CK19), a marker of cholangiocytes and some liver progenitors
[45], were not significantly different between control livers and the
tumors. Levels of Afp were increased in tumors, similar to what is
commonly observed in human HCC [46] (Figure 2B). These
observations indicate that loss of Rb in this mouse model of HCC
induced by expression of MYC does not grossly affect the
histopathological features of these tumors, allowing us to further
investigate how loss of RB and MYC overexpression may function
during HCC development.
Activation of MYC and loss of RB do not cooperate to
control cell cycle progression in the liver of adult mice
Immunofluorescence analysis for Ki67 expression, a marker of
cycling cells, and for BrdU incorporation, a marker of DNA
replication, showed that tumors from both genotypes displayed
high indices of proliferation that were not visibly different
(Figure 3A–B and D). MYC and MYC/Rb mutant tumors also
showed grossly similar levels of apoptotic cell death as detected by
immunofluorescence for cleaved caspase 3 (CC3) (Figure 3C–D).
To corroborate these observations made on tumor sections, we
next measured mRNA and protein expression levels of cell cycle
genes from dissected tumors. We did not detect any significant
differences between MYC and MYC/Rb mutant tumors, which
both expressed high levels of these cell cycle regulators compared
to wild-type livers (Figure 4A–B).
These observations indicated that MYC and MYC/Rb mutant
HCCs were very similar but did not exclude that the early stages
of cancer development may have different characteristics. To
begin to investigate the features of liver cancer initiation in mice
from both genotypes, LAP-tTA TRE-MYC mice were bred to
Rosa26
+/CreER Rb
lox/lox mice, in which recombination of alleles
flanked by lox sites can be triggered by administration of
intraperitoneal injections of tamoxifen. We found that this
approach gave less variable results than the adenoviral infection
at early time points (data not shown) and resulted in the efficient
deletion of Rb (Figure 5A).
Previous studies have shown that activation of the MYC
transgene in the liver of adult mice does not change the
proliferation of hepatocytes compared to wild-type livers [32,42].
In contrast, deletion of Rb is not sufficient to initiate liver cancer
development but has been shown to cause widespread cell cycle-
entry in hepatocytes [44]. We observed that, before any tumor
lesions could be observed histopathologically, Rb mutant mice
displayed elevated Ki67 staining on liver sections compared to Rb
wild-type mice; activation of the MYC transgene did not induce
proliferation in populations of adult hepatocytes, as expected, and
slightly increased the number of Ki67
+ cells in Rb deficient mice,
but this trend was not significant (Figure 5B).
Together, these experiments indicate that loss of RB does not
significantly change the molecular or physical identity of MYC-
induced HCC in this mouse model.
Activation of MYC and deletion of Rb together lead to
increased polyploidy in adult liver cells
We next investigated the potential effects of MYC activation
and Rb deletion on the DNA content of hepatocytes in pre-
neoplastic livers. Previous studies have reported that both
overexpression of MYC alone and inactivation of RB alone in
adult mice leads to an increase in ploidy of hepatocytes
[44,47,48,49,50]. The histopathological analysis of liver sections
from Rb and MYC/Rb mice after 5 months of induction of the
MYC transgene and deletion of Rb showed accumulation of
hepatocytes with large nuclei compared to control mice, before the
appearance of tumors (Figure 5C).
FACS analysis (Figure 5D) showed that activation of MYC
resulted in a non-significant increase in ploidy in hepatocytes after
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stabilization and activation is only effective once tumorigenesis
has been initiated in cells [32,39,42] (DWF, unpublished
observations). Loss of RB led to decreased numbers of 4n
hepatocytes and a concomitant increase of 8n and 16n cells,
consistent with increased polyploidy. Activation of MYC in Rb
deficient mice also generated significantly more 4n hepatocytes
compared to loss of RB alone. MYC/Rb double mutant mice
showed a significant increase in ploidy compared to MYC mutant
mice, with fewer 2n populations and more 8n and 16n populations
(Figure 5D). These observations suggest that loss of RB may be
more influential than activation of MYC in perturbing DNA
content in adult hepatocytes, but also that the two genetic events
cooperate to control endoreduplication of mature hepatocytes
under these experimental conditions.
Rb/MYC double mutant mice die from HCC faster than
MYC mutant mice
MYC and MYC/Rb mutant mice develop tumors that are
histopathologically similar and express comparable levels of cell
cycle regulators. However, it was still possible that loss of RB
function and activation of MYC may cooperate during tumor
development; in particular, MYC/Rb mutant mice have more
polyploid hepatocytes compared to MYC mutant mice before
Figure 1. MYC activation and Rb deletion drive HCC development in the liver of adult mice. A. Strategy to produce MYC and MYC/Rb
mutant tumors using Rb
lox/lox and TRE-MYC LAP-tTA mice. MYC is activated in the liver by the removal of doxycycline from the drinking water while Rb
is specifically deleted in the liver by splenic injection of Ad-Cre. Ad-GFP is used as a control. B. RT-qPCR analysis of MYC RNA levels in control livers
(Rb
lox/lox MYC
Off, n=2) and in MYC and MYC/Rb mutant tumors (n=3). C. Immunoblot analysis of MYC protein levels in control livers (MYC
Off) and in
MYC and MYC/Rb mutant tumors (two independent tumors each, T1 and T2). Actin serves as a loading control. D. Genomic PCR analysis for the
deleted allele of Rb (Rb
D) using DNA from MYC and MYC/Rb mutant tumors. Actin serves as a positive PCR control. E. RT-qPCR analysis of Rb RNA
levels in MYC (black, n=3) and MYC/Rb (grey, n=3) mutant tumors.
doi:10.1371/journal.pone.0019758.g001
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associated with cancer, including liver cancer [51,52]. We tested
this possibility by monitoring the survival of MYC and MYC/Rb
mutantmiceover a year afteractivation ofMYCand deletion ofRb.
As reported before, not all MYC mutant mice develop HCC when
the transgene is induced in adult mice [32,42]. Indeed, we found
that some mutant mice were still alive at 52 weeks and that none of
these mice died from HCC between 52 and 75 weeks. Because mice
tend to develop tumors naturally after one year of age, including
some liver lesions, we focused our analysis on mice aged one year
after the removal of doxycycline. Importantly, none of the control
mice (wild-type for MYC and wild-type or mutant for Rb, n=12)
died from liver cancer within this first year (data not shown).
We found that loss of Rb did not change the number of mice
that do not develop HCC within one year, suggesting that Rb
deletion does not affect cancer initiation and confirming that
tumorigenesis is driven by activation of MYC in this mouse model
(Figure 6A). MYC mutant mice had a median survival of 31 weeks
while the median survival of MYC/Rb mutant mice was 27 weeks;
when the mice that did not die from liver cancer were excluded
from the analysis, the median survival for MYC and MYC/Rb
mutant mice decreased to 27 and 16.5 weeks, respectively, with a
P value of 0.07 in a Gehan-Breslow-Wilcoxon test. Thus, while not
statistically significant, this analysis is indicative of a trend that
MYC/Rb mutant mice die faster from HCC than mice with MYC
activation alone, suggesting that loss of Rb may cooperate with
activation of MYC in HCC.
The possibility to control MYC activation and Rb deletion with
two different methods (removal of doxycycline and Cre-mediated
recombination, respectively) also allowed us to test the possibility
that the order of the mutations in this system may influence tumor
development. While deletion of Rb is not sufficientto initiate cancer,
it results inincreased proliferation and ploidy. We hypothesized that
activation of MYC in this context may facilitate and accelerate
tumor development in the liver. To test this idea, we infected mice
with Ad-Cre and then, one month later, activated MYC by
removing doxycycline from the water. The analysis of these two
cohorts of MYC/Rb mutant mice showed no difference in survival
curves when survival was measured starting at the time of MYC
activation (Figure 6B). Thus, in this context, pre-deletion of Rb does
not affect tumor development in the liver of mice expressing MYC.
Discussion
In this study we investigated if loss of RB function may
cooperate with activation of MYC in a mouse model of HCC.
While RB and MYC are important players in the tumorigenic
Figure 2. Rb inactivation does not change the histology and differentiation status of MYC-induced HCC. A. Histology of non-tumor
liver tissue from MYC mutant mice (left) and tumor tissue from MYC (center) and MYC/Rb (right) mutant mice. B. RT-qPCR analysis of Albumin (a
marker of hepatocytes), CK19 (a marker of bile ducts), and Afp (a marker of HCC) in control livers (white, n=2), MYC mutant tumors (black, n=3), and
MYC/Rb mutant tumors (grey, n=3). Note that the p-value for Afp between control livers and MYC/Rb mutant tumors is 0.06, just below the
significance threshold.
doi:10.1371/journal.pone.0019758.g002
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staining for Ki67 (A), BrdU (B), and cleaved caspase 3 (CC3) (C)o nMYC mutant non-tumor liver tissue and tumor tissue from MYC and MYC/Rb mutant
mice. DAPI nuclear staining is used to indicate the density of cells on the sections. The pictures shown are representative of each group.
D. Quantification of staining shown in A. The number of positively stained cells for each antibody over the number of DAPI stained cells expressed as
a percent was determined using the BioQuant software. For each antibody and genotype combination the average of n=2 mice was calculated
where each n is the average percent of positive cells from three fields containing at least 250 cells each.
doi:10.1371/journal.pone.0019758.g003
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functional interactions have been tested genetically in vivo.W e
found that MYC and MYC/Rb mutant tumors closely resembled
each other, including similar appearances grossly, histologically,
and molecularly. The only identifiable difference was the degree of
ploidy in pre-neoplastic tissue where MYC/Rb mutant pre-tumor
tissue displayed a higher degree of ploidy than MYC mutant pre-
tumor tissue in hepatocyte populations.
Several oncogenes and growth factors, such as E2F1 and TGFa,
have been shown to cooperate with MYC in mouse models of
HCC development [53,54,55,56]. Clearly, tumors induced by
oncogenes such as MYC must have some levels of inactivation of
the RB pathway to be able to grow. However, it is surprising that
we did not observe a strong enhancement of HCC development
when Rb deletion is added to MYC activation, especially given the
observation that many human samples of HCC tend to harbor
mutations that simultaneously activate MYC and inactivate the
RB pathway [57,58]. There are a few possibilities that could
explain this observation. For example, MYC has been shown to
directly induce transcription of Cyclin D2 and Cdk4, which in turn
leads to the sequestration of p27 away from Cyclin E and thus the
accumulation of Cyclin E/Cdk2 complexes; these kinases then
lead to the phosphorylation and inactivation of RB and its family
members p107 and p130 [20,21,22]. In fact, inactivation of MYC
delays phosphorylation of RB after growth stimulation [59].
Moreover, MYC induces the expression of miRNA genes that can
repress the expression levels of Rb and other cell cycle inhibitors
[60]. MYC can also directly activate genes downstream of RB/
E2F complexes [61,62,63]. As a result, it is possible that MYC
activation alone is enough to critically inactive the RB pathway. In
support of this hypothesis, we found that cells expressing high
levels of MYC also express lower levels of Rb mRNA compared to
control hepatocytes (data not shown). However, as mentioned
above, the observation that activation of MYC and loss RB
function are selected for in many cancers, including HCC
[20,21,22,26], would argue against the idea that activation of
MYC is sufficient to inactivate RB function and that loss of both
RB alleles is merely a passenger effect.
Another possibility to explain the absence of strong cooperation
between activation of MYC and deletion of Rb in our mouse HCC
model is that mouse tumors driven by MYC overexpression
develop by different mechanisms than human tumors expressing
high levels of MYC, which would make loss of RB function
dispensable. Thus, it will be interesting in the future to examine
the consequences of deleting Rb in mice in which MYC activation
is achieved using different systems, including different liver
promoters and at different time points during tumorigenesis.
It is also possible that, similar to what has been observed in
the eye of mice [64], the RB family members p107 and p130
have a stronger overlapping role in the mouse liver compared to
t h eh u m a nl i v e r .T h ei d e at h a ti n a ctivation of several RB family
members may be required to observe a strong phenotype during
HCC development is supported by the observation that most of
the events known to inactivate the RB pathway are upstream
events and may inactivate RB, p107, and p130 simultaneously
[65,66,67,68,69,70,71,72,73]. Future experiments may examine
HCC development in MYC/Rb mutant mice in which p107 and
or p130 are also inactivated, as well as the tumor phenotypes of
mice in which Rb is deleted and MYC is activated in other
tissues and organs. In fact, we have previously conducted a
similar study examining the interaction between oncogenic RAS
and loss of Rb in a mouse model of lung adenocarcinoma. In this
model, RAS-induced tumors also showed partial inactivation of
RB function, but loss of Rb had two effects: initially it increased
cancer initiation and then led to decreased proliferation,
presumably due to compensation by p107 and p130 [74]. As
a result it appears that the effects of cooperation between an
oncogene and a tumor suppressor may not be reliably predicted
when based solely on the degree of overlap between their
pathways.
Recent observations indicate that the timing of p53 re-
expression during lung cancer development may affect cancer
outcome [75,76]. The system we employed utilizes the tetracy-
cline-dependent regulatory system to activate MYC and the Cre-
lox conditional mutation system to delete Rb. This enabled us to
investigate the consequences of changing the time of the
tumorigenic events. We hypothesized that prior mutation in the
Rb gene may facilitate MYC-induced tumor development in the
liver but found no differences in HCC development whether Rb
Figure 4. Rb inactivation does not change the mRNA expres-
sion or protein levels of cell cycle markers in MYC-induced
HCC. A. RT-qPCR for several cell cycle genes on RNA from MYC (black,
n=3) and MYC/Rb (grey, n=3) mutant HCC. Rb
lox/lox MYC
Off non-tumor
liver is used as a control (CTRL) (white, n=2). There is not statistical
difference for any of these gene expression levels between MYC and
MYC/Rb tumors. B. Representative immunoblot analysis for several cell
cycle markers on protein extracts from MYC and MYC/Rb mutant HCC
compared to wild-type liver. The concentration of the protein extracts
was quantified using a Bradford assay and similar amounts of proteins
were loaded in each lane. Actin serves as a loading control; note that
CTRL liver cells express less Actin per mg of protein extract than tumor
cells.
doi:10.1371/journal.pone.0019758.g004
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PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19758Figure 5. Rb inactivation and MYC activation cooperate to increase ploidy in hepatocytes. A. Genomic PCR analysis for the deleted allele
of Rb (Rb
D) using DNA from control, MYC, Rb, and MYC/Rb mutant livers before the development of tumors in Rosa26
+/CreER mice. Actin serves as a
positive PCR control. B. Quantification of immunostaining experiments for the number of Ki67
+ liver cells per field on control, MYC, Rb, and MYC/Rb
mutant liver sections 5 weeks after the deletion of Rb and the induction of MYC. The number of positive cells in eight 206fields was counted in 2
mice for each treatment group. The differences observed are not significant in a t-test. C. Representative microphotographs of hepatocytes from a
mouse injected with corn oil alone in the presence of doxycycline (wild-type for RB and MYC) and a mouse injected with tamoxifen in the absence of
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also found that deletion of Rb one month after activation of MYC
did not impact survival (data not shown). These negative results
may be due to the fact that, as discussed above, loss of RB may not
strongly modify the tumor phenotype of MYC-expressing mice in
our model. Evidence from HCC patients suggests that RB loss is a
late event in HCC development [66], and it is possible that a
similar strategy in a different mouse model may identify specific
functions for RB during HCC progression, including during
metastasis [66].
One such function for RB may be to protect genome
integrity. Recent evidence indicates that, in addition to its role
at the G1/S transition of the cell cycle, RB may also play a
critical role to prevent chromosomal instability [77,78,79,80].
While the role of polyploidy in cancer development is still
controversial, increasing evidence suggests that it may result in
aneuploidy, which may contribute to cancer initiation
[51,52,81,82]. We found that loss of RB may increase
polyploidy in MYC-expressing hepatocytes. Recent evidence
also suggests that one mechanism of HCC development upon
infection with hepatitis C virus (HCV) may be through
increased genomic instability following inactivation of RB
[48]. One limitation of our study is that the cell of origin of
the liver tumors developing upon ectopic expression of MYC is
unknown, thereby limiting any further investigation of the
potential role of increased polyploidy in HCC development. It
will be interesting in the future to determine in other cancer
models if activation of MYC and loss of RB cooperate in HCC
development by altering chromosome numbers.
Materials and Methods
Mice
All animal work was approved by Stanford IACUC committee
(protocol number 13565) and follows AAALAC guidelines. TRE-
MYC LAP-tTA mice were bred to either conditional Rb
lox/lox or
Rb
lox/lox Rosa26-CreER mice. The human MYC transgene was
activated by the removal of doxycycline (100 mg/ml) from the
drinking water. Recombination of alleles in Rb
lox/lox mice was
accomplished by splenic injection of 5610
8 pfu Ad-Cre (Vector
Development Laboratory, Baylor). Control mice were treated with
equal amounts of AdGFP (Baylor College of Medicine). The Cre
recombinase was induced in Rb
lox/lox Rosa26-CreER mice by five
consecutive daily injections of 1 mg of tamoxifen (Sigma) in corn
oil; control mice were injected with corn oil alone [83]. All
treatments were performed on adult mice (8–12 weeks old).
Deletion of the Rb gene was monitored by genomic PCR, as
described before [83].
RNA analysis
RNA was extracted with TRIzol (Invitrogen) and cleaned with
the RNeasy Mini Kit (QIAGEN). RT-PCR and quantitative Real-
Time PCR were performed using the DyNAmo cDNA synthesis
kit and the SybrGreenER Mastermix (Invitrogen), respectively.
Primer Sequences: Rb delta forward 59- GGAGAAAGTTT-
CATCCGTGGAT -39 reverse 59- GTGAATGGCATCTCATC-
TAGATCAA -39; human MYC forward 59-TGCTCCATGAG-
GAGACACC-39 reverse 59-CCTCATCTTCTTGTTCCTCCA-
39; p107 forward 59- CCGAAGCCCTGGATGACTT-39 reverse
59- GCATGCCAGCCAGTGTATAACTT-39; p130 forward 59-
TGTCCGGCCTCAGGAATG-39 reverse 59- CTGTCAGCGA-
TAGCCTGAGTTG-39; p53 forward 59- GCCCATGCTACA-
GAGGAGTC-39 reverse 59- AGACTGGCCCTTCTTGGTCT-
39; p21 forward 59-CAGATCCACAGCGATATCCA-39 reverse
59-GGCACACTTGCTCCTGTG-39; E2f1 forward 59-TGCC-
AAGAAGTCCAAGAATCA-39 reverse 59-CTTCAAGCCGCT-
TACCAATC-39; Cyclin E1 forward 59- CTGAGAGATGAG-
CACTTTCTGC-39 reverse 59- GAGCTTATAGACTTCGCA-
CACCT-39; B-myb forward 59-TTACGCCGTACGTGGAAGA-
39 reverse 59-TTCCAGTCTTGCTGTCCAAA-39; cdc25c for-
ward 59- GGAAACACCCGGATCTGAA-39 reverse 59- ACT-
TTCCAGACAGCAAAGCAG-39; Cyclin A2 forward 59-CTT-
GGCTGCCACCAACAGTAA-39 reverse 59-CAAACTCAGTT-
CTCCCAAAAACA-39; GAPDH forward 59-GGGTTCCTA-
TAAATACGGACTGC-39 reverse 59-CCATTTTGTCTACGG-
GACGA-39; Afp forward 59- TGCTGCAAAGCTGAAAATGC -
39 reverse 59- GCTGCTTTCTCTTAATTCTTTTGTAACTG -
39; Albumin forward 59-AGTGTTGTGCAGAGGCTGAC-39
reverse 59-TTCTCCTTCACACCATCAAGC-39; CK19 forward
Figure 6. Survival analysis of Myc and Myc/Rb mutant mice.
A. Kaplan-Meier survival analysis of MYC (n=27) and MYC/Rb (n=19)
mutant mice when both tumorigenic events were triggered simulta-
neously (time 0) in adult mice (8–12 weeks after birth) by removal of
doxycycline and Ad-Cre infection. B. Survival analysis of MYC/Rb mutant
mice developing HCC when both tumorigenic events were triggered
simultaneously in adult mice (8–12 weeks after birth) (n=19) and when
Rb deletion by Ad-Cre was performed 4 weeks before MYC activation
(8–12 weeks and 12–16 weeks after birth, respectively) (n=15); time 0 is
the time of MYC activation.
doi:10.1371/journal.pone.0019758.g006
doxycycline are shown (MYC/Rb mutant liver). Arrows show a small nucleus in the control mouse and a large nucleus in the mutant mouse.
D. Quantification of ploidy by FACS of hepatocyte populations from control (n=5), MYC (n=8), Rb (n=5), and MYC/Rb (n=8) mutant livers 5 months
after Rb deletion (Rosa26
+/CreER mice) and MYC activation. Only statistically significant differences are shown.
doi:10.1371/journal.pone.0019758.g005
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Immunoblot analysis
Whole cell extracts from tissue were prepared in 50 mM Tris
pH 7.4, 250 mM NaCl, 10% glycerol, 0.5% Triton-X-100, and a
cocktail of protease inhibitors. 75 mg of protein extract were run
on acrylamide gels and transferred to a PVDF membrane
(Hybond). Membranes were probed with the following antibodies:
CDK2 (Santa Cruz Biotechnology, sc-163-G), Cyclin E1 (Santa
Cruz Biotechnology, sc-198), E2F1 (Santa Cruz Biotechnology, sc-
193X), p107 (Santa Cruz Biotechnology, sc-318), p53 (Vector
Laboratories, CM5), PCNA (Santa Cruz Biotechnology, PC10),
and b-Actin (Sigma, A5441). Secondary antibodies conjugated to
HRP (Jackson ImmunoResearch) were used at a concentration of
1:5000, and signal was detected by ECL (Invitrogen).
Histology and Immunostaining
Mouse organs were fixed in 4% paraformaldehyde overnight
and embedded in paraffin. Sections were stained with hematoxylin
and eosin (H&E). The histopathological analysis was performed
blind by a trained pathologist (H.V.). Mice were injected with
1 mg of BrdU (Sigma) 4 hours prior to dissection. Sections were
dewaxed and rehydrated in Trilogy buffer (Cell Marque) in a
pressure cooker for 15 minutes, blocked in 5% serum for 30 min,
and incubated with primary antibody overnight at 4uC. The next
day, sections were incubated with secondary antibody for 1 hour,
stained with DAPI (for immunofluorescence) or hematoxylin (for
immunohistochemistry), and mounted. Antibodies used include
Ki67 (Becton-Dickinson, 550609), BrdU (Becton-Dickinson,
347580), and Cleaved Caspase-3 (CC3, Cell Signaling, 96645).
Quantification of cell cycle and cell death was performed using the
BioQuant imaging analysis software.
Flow cytometry
Hepatocyte nuclei were extracted by grinding murine liver in
Lysis Buffer (25 mM Tris pH 7.5, 50 mM KCl, 2 mM MgCl2,
1 mM EDTA, and 1 mM PMSF), followed by homogenization
and centrifugation at 12,000 rpm for 30 seconds [49]. Pellets were
then resuspended in Lysis Buffer and centrifuged again at
12,000 rpm for 30 seconds. These pellets were then resuspended
in PI Buffer (0.5 mg/ml Propidium Iodide, 0.1% NP-40, 0.1%
Sodium Citrate, 40 mg/ml RNase A, in PBS) for 30 min. FACS
analysis was performed with a BD FACSCalibur instrument and
data was analyzed using the FlowJo software (Tree Star).
Statistical analyses
Statistical significance was assayed by Student’s t-test using the
GraphPad Prism software, except for Figure 5D where ANOVA
was used to compare the four genotypes for each ploidy analyzed
and for Figure 6 where the Gehan-Breslow-Wilcoxon test was used
to compare the survival of mouse cohorts. Mean and standard
error are shown. ns, not statistically significant, *, p,0.05 -
** p,0.005 - ***, p,0.001.
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